J&J sees positive late-stage data for Caplyta in reducing bipolar manic symptoms

Phase 3positiveCaplytaPositive

AI Analysis

Summary

Johnson & Johnson announced positive late-stage trial data for Caplyta in reducing bipolar manic symptoms, supporting the drug's efficacy profile in this indication.

Clinical Trial Data

Phase

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.70

J&JCaplytabipolar maniaPhase 3positive data

Related Companies

$JNJ

Read the original article

Published by Seeking Alpha Healthcare on September 21, 2026 3:43 PM

Read Original